

Clinical Policy Title:	HIV
Policy Number:	RxA.876
Drug(s) Applied:	Biktarvy, Cabenuva, Genvoya, Juluca, Odefsey, Symtuza, Triumeq
Original Policy Date:	4/10/2025
Last Review Date:	12/11/2025
Line of Business Policy Applies to:	All lines of business (except Medicare)

Criteria

I. Initial Approval Criteria

A. HIV treatment (must meet all):

1. Trial and failure of Dovato, unless one the following is met (a, b, c, d, or e):
 - a. History of long acting cabotegravir (CAB-LA) use as PrEP;
 - b. HIV RNA >500,000 copies/ml;
 - c. Hepatitis B or C infection;
 - d. Drug disease or drug-drug interactions with Dovato;
 - e. Hypersensitivity reactions to dolutegravir
2. Applies to new starts only confirmed by claims or documentation.

Approval duration

All Lines of Business (except Medicare): Approval duration: 12 months

II. Continued Therapy Approval

- a. Auto-approval based on lookback functionality within the past 120 days, as a proxy for member responding positively to therapy with RxAdvance initial approval.

Approval duration

All Lines of Business (except Medicare): Approval duration: 12 months

References

1. WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. www.who.int. Published July 16, 2021.
<https://www.who.int/publications/i/item/9789240031593>
2. American Academy of HIV Medicine | HIV Treatment Guidelines. Aahivm.org. Published 2010.
<https://aahivm.org/hiv-treatment-guidelines/>
3. Package Insert: [DOVATO-PI-PIL.PDF](#)

Review/Revision History	Review/Revised Date	P&T Approval Date
Policy established.	4/10/2025	4/10/2025
Policy reviewed	12/11/2025	12/11/2025

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.